We also utilized the submap algorithm [27] to compare the similarity of the expression profiles between the two subgroups of glioma patients and 47 previous melanoma patients with detailed immunotherapeutic information, and revealed that patients in FCER1G-high subgroup were more responsive to anti-PD1 treatment (Bonferroni corrected P value = 0.008) (Additional file 5 Fig. 4b), which was consistent with the previous conclusions (Additional file 6: Fig. 5). This evidence concerns the gene PDCD1 and central nervous system cancer.